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Abstract
Background—We have previously reported operational tolerance in patients receiving HLA-
mismatched combined kidney and bone marrow transplantation (CKBMT). We now report on
transient multilineage hematopoietic chimerism and lymphocyte recovery in five patients
receiving a modified CKBMT protocol, and evidence for early donor-specific unresponsiveness in
one of these patients.
Methods—Five patients with end-stage renal disease received CKBMT from HLA-mismatched,
haploidentical living related donors following modified non-myeloablative conditioning.
Polychromatic flow cytometry (FCM) was used to assess multilineage chimerism where evaluable
and lymphocyte recovery post-transplant. Limiting dilution analysis was used to assess helper-T-
lymphocyte reactivity to donor antigens.
Results—Transient multilineage mixed chimerism was observed in all patients but chimerism
became undetectable by 2 weeks post-CKBMT. A marked decrease in T and B lymphocyte counts
immediately following transplant was followed by gradual recovery. Initially recovering T cells
were depleted of CD45RA+/CD45RO− “naïve-like” cells, which have shown strong recovery in
two patients and CD4/CD8 ratios increased immediately following transplant but then declined
markedly. NK cells were enriched in the peripheral blood of all patients following transplant.
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For Subject 2, a pre-transplant limiting dilution assay revealed T helper cells recognizing both
donor and third-party PBMCs. However, the anti-donor response was completely undetectable by
Day 24, while third-party reactivity persisted.
Conclusion—These results characterize the transient multilineage mixed hematopoietic
chimerism and recovery of lymphocyte subsets in patients receiving a modified CKBMT protocol.
The observations are relevant to the mechanisms of donor-specific tolerance in this patient group.
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Introduction
Two major barriers to solid organ transplantation are chronic graft rejection and
complications that arise from long-term global immunosuppression, including increased
incidence of opportunistic infections and malignancies. Induction of mixed chimerism by
nonmyeloablative conditioning followed by bone marrow transplantation (BMT) has the
potential to overcome these barriers by inducing a state of donor-specific unresponsiveness
while leaving the recipient's immune system intact. The validity of this approach has been
supported by studies in murine and large animal models (1). Recently, the approach has
been used to induce long-term acceptance of HLA-mismatched renal allografts without
maintenance immunosuppression for 4-7 years in four of five patients (2). These patients
exhibited transient multilineage chimerism that lasted no more than 21 days, and gradual
lymphocyte recovery following transplant (Andreola et al, manuscript submitted).
We report here on multilineage chimerism and recovering lymphocyte subsets in an
additional 5 patients undergoing a modified CKBMT protocol by methods of polychromatic
FCM. We also describe the rapid development of donor-specific tolerance among IL-2
producing T cells in one of these patients.
Results
Development of a flow cytometric method for reliable assessment of lineage-specific
chimerism
An optimal recipient HLA antigen-specific mAb was identified for Patients 1, 2, 4 and 5,
while no reliable donor or recipient HLA antigen-specific antibody was identified for Patient
3. Any cells negative for the HLA antigen-specific antibody were thus considered to be of
donor origin.
For Patients 1 and 2, no leukocyte marker was used to distinguish between lymphocytes and
erythrocytes in the lymphocyte forward/side-scatter gate area. Thus, lymphocyte chimerism
was not evaluable, since MHC-I-negative erythrocytes present in the lymphocyte gate were
indistinguishable from donor lymphocytes (Figure 1A). This was especially problematic due
to a high percentage of erythrocytes resulting from lymphopenia during the immediate post-
transplant period. The subsequent addition of an anti-CD45 antibody allowed us to analyze
lymphocyte chimerism in Patients 4 and 5 (Figure 1B).
For Patient 4, a positive shift in MHC-I expression on leukocytes occurred during the post-
transplant period (data not shown), making the donor-recipient HLA cell distinction
somewhat unclear. Thus, a pan-MHC-I antibody was added to the chimerism analysis for
Patient 5 to allow improved separation of cells staining with the antigen-specific mAb. For
Patient 5, the use of anti-CD45 as well as pan-MHC-I mAbs allowed highly reliable
LoCascio et al. Page 2













chimerism analysis in monocyte, granulocyte and lymphocyte lineages, as well as analysis
of rare lymphocyte subsets such as natural killer (NK) and natural killer T (NKT)-like cells,
defined as MHCI+/CD45+/CD56+/CD3− and MHC-I+/CD45+/CD56+/CD3+, respectively
(Figure 1C).
Specific T-cell subsets were evaluable for chimerism in all patients by virtue of CD3, CD4
and CD8 markers distinguishing them from MHC-I-negative erythrocytes. Monocytes
(CD14+/CD45+) were also evaluable for chimerism in all patients.
Transient Multilineage Mixed Chimerism
For all four patients for whom a suitable recipient-specific mAb was identified, transient
multilineage chimerism was observed. Monocyte chimerism was detected at peak levels of
20.7 (Day 2), 65.1 (Day 7), 55.5 (Day 10) and 60.1% (Day 7) for Patients 1, 2, 4 and 5,
respectively. Donor T-cell chimerism was also detected in all patients, for both CD3+/CD4+
and CD3+/CD8+ T cells. In all four patients, donor T-cell chimerism peaked on Day 7 post-
transplant, and was undetectable by Day 14. Donor CD4+ T cells peaked at 11.8, 37.5, 6.1
and 4.5%, and CD8+ T cells peaked at 22.6, 9.5, 3.8 and 5.2% for Patients 1, 2, 4 and 5,
respectively.
NK and NKT cell-like chimerism was also evaluable and detected in Patient 5, at levels of
48.0 and 21.4%, respectively, on Day 7 (Figure 1D).
Although chimerism was not evaluable by FCM in Patient 3, total WBC chimerism was
confirmed by PCR assays of variable short tandem repeats as previously described (3-4),
and followed a similar time-course to the other patients.
Lymphocyte Subset Recovery
Due to the conditioning treatment, a dramatic decrease in T-cell counts occurred in all
patients immediately following transplant, reaching 0-12 cells/μL by Day 10. Four patients
then showed a transient increase in T cells that peaked at Week 2 for Patients 1 and 5, and at
Week 3 for Patients 3 and 4, at 151±58 cells/μL (data not shown). All patients had a
subsequent decline in and then gradual recovery of T cells, with most recent values of 267
(Day 499), 143 (Day 364), 776 (Day 388), 691 (Day 317) and 461 (Day 234) cells/μL for
Patients 1-5, respectively (Figure 2).
At one week post-transplant, there was a transient increase in the CD4/CD8 ratio that peaked
on Day 7 for all patients (Figure 3A). The ratios increased from pre-transplant (Day 0 for
Patient 1) values of 1.11, 2.50, 0.71, 1.01 and 1.68, to Day 7 levels of 3.59, 11.07, 7.13, 1.81
and 2.75, respectively, for Patients 1-5, although this increase just missed statistical
significance (P=0.067). The CD4/CD8 ratios then declined to below pre-transplant levels for
all patients by Day 14 (p<0.05). In Patients 2 and 4, this inverted ratio has been sustained
until the present (Days 364 and 317). Patient 1 recovered to Day 0 values by Day 27, and
maintained a stable ratio at most points thereafter, while Patient 3 did not recover until Day
245. After the decline by Day 14, the CD4/CD8 ratio in Patient 5 was dramatically increased
on Days 21, 31 and 57, largely because CD8 T cells were completely undetectable at the
latter two time points, while small numbers of CD4 cells were spared following
administration of ATG.
B cells were also effectively depleted in all patients, reaching <1 cell/μL by Day 7, and
remaining at nearly undetectable levels for >180 days. Strong B cell recovery has been
observed in Patients 1 and 2, with most recent values of 273 (Day 499) and 163 (Day 364)
cells/μL, respectively. Patient 3 has shown some recovery, with 38 cells/μL on Day 388. The
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remaining two patients have yet to recover B cells at Days 317 and 234, respectively (Figure
2).
A trend to an increase (though not statistically significant) in blood NK cell counts was
observed in all patients following conditioning, and this became the dominant lymphocyte
population in all patients, peaking at 238±136 cells/μL (67.0±17.9% of lymphocytes) within
the first 121 days, in comparison to 79±37 cells/μL (7.2±3.9% of lymphocytes) pre-
transplant (Figure 2). The increase in percentage of NK cells from pre-transplant to peak
values was statistically significant (p<0.01). NK cells remained dominant for >280 days in
Patients 1 and 2, 156 days in Patient 5, 39 days in Patient 3, and predominated at only one
time point in Patient 4 (Figure 2).
“Memory” vs. “naïve-like” recovering T cells
CD4+ T cells included a reduced percentage of “naïve-like” (CD45RA+/CD45RO−) cells
following transplant in all patients except Patient 1, for whom pre-transplant data was not
evaluable. This phenotype was paralleled by an increased proportion of “memory-like”
CD3+/CD4+ cells (CD45RA−/CD45RO+), which has remained the dominant phenotype
until the present in Patients 1-3, while the percentage of naïve CD4+ T cells has increased to
levels of 52.1% at Day 317 and 42.8% at Day 234 in Patients 4 and 5, respectively (Figure
3B). Consistently, in Patients 2, 4 and 5, the percentage of “naïve” CD3+CD8+ cells
(CD45RA+/CD45RO−/CD62L+) was decreased following transplant, though low numbers
precluded reliable evaluation in Patient 5 between Days 14 and 108. Such changes were not
evaluable in Patients 1 and 3, since pre-transplant data for this phenotype was not obtained.
Early Donor-Specific Unresponsiveness
Limiting dilution analysis was used to assess helper-T-lymphocyte (HTL) reactivity to donor
and third-party PBMCs for samples obtained from Patient 2 pre-transplant and at Day 24.
Because the frequencies of positive wells did not follow a Poisson distribution upon serial
dilution, it was not possible to accurately determine the frequencies of reactive T cells.
Nevertheless, marked changes in responses were evident upon analysis of frequencies of
responding wells. HTLs were detected that were reactive to donor or third-party PBMCs
pre-transplant. However, by Day 24, the anti-donor response was completely undetectable
(no positive wells), while third-party reactivity persisted. A constant, low level of
autoreactivity was observed both pre-transplant and at Day 24 (Figure 4).
Discussion
We describe here the development of a reliable polychromatic flow cytometric method for
assessment of lineage-specific chimerism under lymphopenic conditions. By including anti-
CD45 mAb in our gating scheme, we excluded erythrocytes that would have otherwise
appeared as negative for the HLA antigen-specific mAb. Furthermore, the addition of an
anti-pan-MHC-I mAb allowed us to compensate for overall shifts in MHC-I expression on
leukocytes. Whether these shifts represented true up-regulation of MHC-I by leukocytes or
simply increased fluorescence intensity due to a higher antibody-to-leukocyte ratio post-
transplant is not clear. In either case, the modified method for detection of lineage-specific
chimerism should permit improved characterization of chimerism in future patients
undergoing CKBMT and HLA-mismatched hematopoietic cell transplantation (HCT) alone.
Multilineage chimerism was observed in the first two weeks in all evaluable patients and
included monocyte, granulocyte, lymphocyte, T cell, NK cell and NKT or NKT cell-like
chimerism. Because donor T cell chimerism was detected as early as 1 week post-transplant
in all 4 patients in whom it was evaluable by FCM, it seems likely that these were donor T
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cells that survived despite MEDI-507 treatment, since maturation and selection of T cells
through a recently irradiated adult thymus could not take place in such a short time. The
very transient nature of chimerism in all lineages raises the possibility that chimerism in all
lineages reflects engraftment of transplanted progenitors but not of hematopoietic stem cells
(HSCs). In such a scenario, the loss of chimerism would not be due to rejection of the donor
marrow, but instead could reflect failure to create sufficient hematopoietic “space” for
engraftment of the relatively small number of donor HSCs administered. Indeed,
cyclophosphamide, the only marrow-toxic agent included in our regimen, is only mildly
toxic to HSCs.
Although marrow rejection would be inconsistent with the long-term renal allograft survival
and rapid development of tolerance in the HTL assay, the rapid loss of donor chimerism
may be an immunological event, possibly mediated by recipient CD8 T cells. Several of the
patients developed an engraftment syndrome early post-transplant that was associated with
renal dysfunction and accumulation of expanding recipient CD8 T cells in the glomeruli, but
did not produce a rejection pattern (Farris et al, manuscript in preparation). The early
development of tolerance among peripheral blood HTLs and the long-term donor-specific
unresponsiveness in in vitro assays (2) (Andreola et al, manuscript submitted) is also
inconsistent with an early rejection mechanism in these patients. Further studies are needed
to elucidate the mechanisms of early chimerism loss and the associated engraftment
syndrome.
The ability of donor NK cells to rapidly repopulate the periphery from progenitors (5-7) may
help to explain their high peak chimerism levels in Patient 5. Early detection of high levels
of monocyte chimerism (as early as Day 2 in Patient 1) was probably supported by rapidly
dividing monocyte progenitors (8) from the donor marrow. While we were able to detect
CD3+/CD56+ cell chimerism in Patient 5, it is unclear whether these are NKT cells or
conventional T cells that express CD56 (9-10), which comprise a significant portion of
CD56+ cells in humans (9). Further studies should allow us to determine the level of
reconstitution of “classical” invariant NKTs (iNKTs), which typically comprise the majority
of NKT cells (11) and can be identified by their expression of the invariant TCR-α chain,
Vα24Jα18. The differing level of donor chimerism in the CD3+/CD56+ subset compared to
conventional T cell and NK cell chimerism levels in Patient 5 is consistent with the
possibility that these represent a distinct cell lineage, such as NKT cells.
Clearly, the infusion of donor bone marrow at the time of kidney transplant has a tolerogenic
impact on the host immune system, as is evident from our studies in monkeys (12), and from
the fact that ten of eleven patients receiving our previous (2,13) and current CKBMT
protocols underwent successful withdrawal from immunosuppression while maintaining
stable renal allograft function. However, the mechanisms of tolerance in the current human
protocol are not fully understood. In mouse models of durable mixed chimerism, the life-
long contribution of donor hematopoiesis to APCs that mediate central deletion of donor
reactive T cells by presenting donor antigen in the thymus is the major mechanism of long-
term tolerance (1). The transient nature of peripheral chimerism in these patients and in
monkeys undergoing similar conditioning regimens (12-14), on the other hand, suggests that
alternate mechanisms of tolerance may be of equal or greater importance in this setting.
Peripheral T regulatory cells (Tregs) have been implicated in allograft tolerance, and we
have previously described their enrichment in recipients of allo-BMT with non-
myeloablative conditioning that involved MEDI-507 (15) and in the first series of CKBMT
patients (Andreola et al, manuscript submitted). Furthermore, a high level of FoxP3
expression in the kidneys of patients from our previous CKBMT protocol suggests the
presence of Tregs in the graft itself (2), while flow cytometric analysis of the current
LoCascio et al. Page 5













patients also suggests a marked enrichment for peripheral Tregs due to both recent thymic
emigration and peripheral expansion (Morokata et al, manuscript in preparation).
Analysis of lymphocyte subsets in all five patients revealed marked depletion of T cells
post-transplant, followed by a transient early increase, decline, and then gradual persistent
recovery. The use of ATG to treat engraftment syndrome complicated the T cell depletion
observed in some patients and delayed T cell recovery. The initial recovery of T cells was
likely due to lymphopenia-driven proliferation of recipient and donor T cells, as
thymopoiesis was likely impaired following irradiation. This is further supported by the fact
that both CD4 and CD8 T cells were predominated by a “memory-like” phenotype following
transplant, consistent with data in a humanized mouse model definitively showing that naïve
human T cells convert to the effector/memory phenotype when placed in a lymphopenic
environment (16). Alternatively, memory-like T cells may have been preferentially spared
by conditioning. The sustained memory phenotype in Patients 1-3, especially within the
CD4 subset, suggests that these patients have not regained robust thymus-dependent
generation of CD45RA+ T cells, whereas evidence for such recovery was obtained in the
latter two patients. This is consistent with the age-dependent nature of thymic recovery in
adults (17), considering that the first three patients were each over 35 years old at the time of
transplant, in comparison to Patients 4 and 5, who were 22 and 26 years old, respectively.
Despite CD4/CD8 ratio inversion, which can be associated with the occurrence of
opportunistic infection due to low CD4 T cell counts (18-19), no serious infections have
occurred in any of the patients to date.
Since NK cells were the dominant lymphocyte lineage for a prolonged period of time in four
of five patients following transplant, it is important to understand the role of this subset in
recipients of our protocol. Typically, NK cells are among the first lymphocytes to repopulate
the periphery following HCT, when they are predominantly CD56highCD16low, with low
cytotoxicity and a high capacity for cytokine production. In contrast, the peripheral blood
NK cells in normal individuals are predominantly CD56dimCD16high and have high cytolytic
activity (20-22). In our previous analysis of patients receiving HCT with MEDI-507, we
found that early recovering NK cells lacked cytolytic function in vitro (5). However, they
also expressed uncharacteristically low levels of CD2, a marker which has been associated
with the more cytotoxic subset of NK cells (22). Anti-CD2 mAb (MEDI-507) treatment may
have been responsible for this phenotype. While we have yet to extensively examine NK
cells in the current study, we will better characterize these cells in future patients by refining
our FCM methods to include CD2, CD3, CD16, CD45 and CD56 markers to distinguish
among these subsets.
The strong recovery of NK cells in the current patients probably reflects an increased
availability of IL-15 due to T-cell depletion, which has been reported to enhance their
development and contribute to NK cell homeostasis (23-24). The presence and expansion of
NK cells in this context might be beneficial for a number of reasons, one being that in a
lymphopenic environment, they can inhibit homeostatic CD8 T cell proliferation through
IL-15 competition, thereby potentially decreasing the risk of early T cell-mediated allograft
rejection (25). A number of other NK-associated immunoregulatory properties have been
described, including killing (26) and regulation (27) of activated T cells, as well as secretion
of regulatory cytokines like TGF-beta, which has been induced in vitro by administration of
anti-CD2 (28), as well as by exposure to apoptotic cells, which in turn suppressed CD4 T
cell proliferation and activation (29). The presence of NK cells during lymphopenia may
have also served as a protective barrier against opportunistic infections.
The in vitro assay we performed with early post-transplant PBMCs from Patient 2 provides
evidence for the very early development of donor unresponsiveness among HTLs. While the
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anti-third party response was also reduced at this time, the donor-specific response was
completely undetectable, despite the recent loss of donor chimerism and the presence of
donor antigen in the kidney graft. Whether this unresponsiveness was due to early deletion
of donor-reactive CD4 T cells, specific anergy or the presence of peripheral regulatory
mechanisms is not clear. Further functional and phenotypic analyses of the lymphocytes




In a study sponsored by the Immune Tolerance Network (ITN), five patients with end-stage
renal disease received CKBMT from HLA-haploidentical living related donors on Day 0.
BMT included an average of 2.5±(SD)0.3×108 nucleated cells, 22.0±7.5×106 CD3+ cells
and 2.0±0.4×106 CD34+ cells per kilogram. Non-myeloablative conditioning included anti-
CD20 mAb (Rituximab) (Biogen Idec Inc. and Genentech USA, Inc., South San Francisco,
CA, USA) administered on Days -7, -2, 5 and 12, anti-CD2 mAb (MEDI-507) (MedImmune
Inc., Gaithersburg, MD, USA) given on Days -2 (test dose), -1, 0 and 1, and 7 Gy thymic
irradiation on Day -1. Cyclophosphamide (MeadJohnson, Princeton, NJ, USA), was
administered on Days -5 and -4. Prednisone was started at approximately 2 mg/kg on Day 4
and then tapered off by Day 31 for all patients except Patient 3, who received an additional
course from Days 31 to 215. Additional immunosuppression that was given in response to
early clinical events will be described elsewhere and is indicated in Figure 2 only in order to
facilitate interpretation of lymphocyte recovery data. Immunosuppression was successfully
discontinued in patients 1, 2, 4 and 5 at days 238, 245, 256 and 244. The clinical details of
and rationale for the treatments listed here will be described elsewhere (Kawai et al,
manuscript in preparation).
Flow cytometry
Polychromatic FCM was performed with the use of an LSR II flow-cytometer (BD
Biosciences, Mountain View, CA, USA), as described elsewhere (13), to analyze peripheral
white blood cells (WBC) stained with fluorochrome-labeled anti-HLA class I antigen-
specific mAbs (One Lambda, Inc., Canoga Park, CA, USA), and anti-CD3, CD4, CD8,
CD14, CD19, CD25, CD45, CD45RA, CD45RO, CD56 (BD Biosciences) and CD62L
(Invitrogen, Carlsbad, CA, USA) mAbs. Data analysis was performed with FlowJo (Tree
Star Inc., Ashland, OR, USA). Gates were established using pre-transplant or late post-
transplant samples, in which the large number of lymphocytes made separations between
cell populations clear. Gates were kept constant throughout analysis for each patient where
possible. Lymphocyte subset percentages were determined by dividing the percentage of
cells gated for a given phenotype by the percentage of CD45+ cells within the lymphocyte
gate, and then multiplying by 100. This formula was necessary to compensate for non-
lymphocytes (CD45− cells) present in the lymphocyte forward/side-scatter gate. Absolute
numbers of lymphocyte subsets were calculated by multiplying the percentage of each
subset out of all lymphocytes by the absolute lymphocyte count determined from the clinical
differentials at each time point (% subset out of lymphocytes) × ((WBC/μL)/
(%lymphocytes)). For chimerism analysis in specific cell lineages, the total gated cells in
that lineage (defined by the indicated mAb combinations) were used as the denominator
population.
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Limiting dilution assay for helper-T-lymphocyte reactivity
Graded numbers of responder PBMCs were tested in 24 replicate wells each as described
previously (30). Positive wells were defined as those producing cpm>3 standard deviations
above the mean of the 24 control wells containing stimulators alone.
Statistical Analysis
Statistical analysis was performed using Microsoft Excel (Microsoft Corporation, Redmond,
WA). A two-tailed paired T-test was applied, except for analysis of % natural killer cells,
where a two-tailed, two-sample equal variance T-test was applied, since pre-transplant data
were not available for Patient 1.
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Development of a flow cytometric method for reliable assessment of lineage-specific
chimerism. (A) For Patients 1 and 2, gating of lymphocytes by forward/side-scatter followed
by analysis of recipient HLA expression yielded unreliable levels of chimerism due to
inclusion of HLA-negative erythrocytes in the gate. Monocyte and T-cell chimerism was
interpretable (not shown). (B) The addition of anti-CD45 mAb for Patient 4 resulted in
exclusion of erythrocytes and more reliable monocyte and lymphocyte chimerism. (C) The
addition of anti-pan-MHC-I mAb for Patient 5 allowed for highly reliable chimerism
analysis in rare subsets post-transplant, such as CD3+CD56+ NKT-like cells. (D) Levels of
lineage-specific donor chimerism are shown for Patients 1, 2, 4 and 5 where evaluable by
FCM.
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Absolute numbers of lymphocyte subsets (cells/μL) are shown for Patients 1-5. Time points
at which the data were not evaluable are indicated by “N/A.” Administration of additional
immunosuppression, as well as the time of complete withdrawal from immunosuppression is
indicated in days post-transplant for each patient.
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Characterization of recovering T cells. (A) CD4/CD8 ratios for each of the five patients are
shown for the duration of follow-up thus far (left panel). The x-axis is expanded to show the
transient increase in the CD4/CD8 ratio at Day 7, followed by inversion to a CD8 dominant
phenotype (right panel). Ratios for Patient 5 between Days 14 and 108 are not shown, since
there were no detectable CD8 T cells at these time points. Other time points at which data
were not evaluable are left blank. (B) Percentages of naïve-like CD4 T cells (CD45RA+/
CD45RO−) and CD8 T cells (CD45RA+/CD45RO−/CD62L+) out of all CD4 and CD8 T
cells are shown, respectively, for each of the five patients. Pre-transplant data for Patient 1
was not evaluable for CD4 or CD8 T cells, and CD62L analysis was not possible for Patient
3. These time points are left blank.
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The number of wells (out of 24 wells) in which reactive IL-2 producing T cells were
detected are displayed for each responder/target combination, at each dilution (number of
responder PBMCs per well). Responders included PBMCs obtained from Patient 2 pre-
transplant (PreTX), Patient 2 at Day 24 post-transplant (Day 24) and donor. Irradiated
targets included PBMCs obtained from Patient 2 pre-transplant (PreTX), donor and a third
party. Donor-reactive IL-2 producing T cells were completely undetectable at Day 24, while
third-party reactivity persisted.
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